Alexion

Alexion

Alexion

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem. Sign in

Alexion

Address

Dublin, N.A., Ireland

Contact

alexion.ireland@alexion.com

Description

The entity profile has not yet been completed.

This entity is yours?
Sign in to update information and position your organization seamlessly within the European bioproduction Value Chain. Benefit from the geolocated map to showcase your expertise, projects, and initiatives. Boost your visibility and make meaningful connections within the ecosystem.

Matchmaking

Connect with Alexion

Position on the value chain

With the ultimate aim to create a European alliance for bioproduction in Europe, organisations have joined forces with COBIOE. Discover who are our associates.

Bio-resources and biobanking
  • Cells, tissues and humanized xeno-organs
  • Biosamples
  • Viral, phage or bacterial specimen
Identification of biotherapies
  • Target identification
  • Target validation
  • Screening
Drug design
  • Drug assessment
  • Drug engineering
  • In vitro preclinical studies
Clinical validation
  • Clinical trials
  • In vivo preclinical validation
  • Pre-industrial scale production
Production
  • Upstream processes
  • Downstream processes
  • Quality control
Market access
  • CE mark / market authorisation
  • Payment / Reimbursement
  • Care pathways

Alexion last news

14/06/2024

J.P. Morgan has officially jumped into early stage biotech investing

J.P. Morgan Life Sciences Private Capital, a small team within the investment banking giant, closed its first fundraising, bringing in more than $500 million to invest in life science startups.…

14/06/2024

Intellia Therapeutics Names Brian Goff to its Board of Directors

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA ), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. "We are very pleased to welcome Brian to our board of directors. Brian's extensive global commercialization experience, coupled with his track record of success leading rare disease product launches, will be invaluable to Intellia as we commercialize our first CRISPR-based gene editing therapies for people with life-threatening diseases," said Intellia President and Chief Executive Officer John Leonard, M.D. "We look forward to leveraging Brian's first-hand experience to guide us through the exciting evolution from late-stage clinical development to a commercial organization as we continue to lead a new era in medicine." Mr. Goff joins the Intellia board of directors with over three decades of commercialization, operations and sales and marketing experience at leading biopharmaceutical companies. He is a seasoned and accomplished executive global leader focused on rare diseases. Since 2022, he has been the chief executive officer of Agios Pharmaceuticals and a member of its board of directors. He previously served as executive vice president, chief commercial and global operations officer of Alexion Pharmaceuticals until its acquisition by Astraeneca in 2021. Prior to Alexion, Mr. Goff was chief operating officer and a member of the board of directors of Neurovance until its acquisition by Otuska Pharmaceuticals. Before joining Neurovance, Mr. Goff served as executive vice president and president of ... Full story available on Benzinga.com

14/06/2024

Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI(TM) (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024

Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI(TM) (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre